Quest diagnostics to offer fda-cleared fujirebio blood test for alzheimer's disease

Test to be available for clinical and research use as soon as this summer, building on quest's pioneering blood-based ad-detect™ product line for assessing symptomatic patients secaucus, n.j. , july 9, 2025 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the lumipulse® g ptau 217/Β-amyloid 1-42 plasma ratio in-vitro diagnostic (ivd) test from fujirebio, a global leader in the field of high-quality ivd testing.
DGX Ratings Summary
DGX Quant Ranking